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Oligometastatic disease has been proposed as an intermediate state between localised and systemically metastasised 
disease. In the absence of randomised phase 3 trials, early clinical studies show improved survival when radical local 
therapy is added to standard systemic therapy for oligometastatic disease. However, since no biomarker for the 
identification of patients with true oligometastatic disease is clinically available, the diagnosis of oligometastatic 
disease is based solely on imaging findings. A small number of metastases on imaging could represent different 
clinical scenarios, which are associated with different prognoses and might require different treatment strategies. 
20 international experts including 19 members of the European Society for Radiotherapy and Oncology and European 
Organisation for Research and Treatment of Cancer OligoCare project developed a comprehensive system for 
characterisation and classification of oligometastatic disease. We first did a systematic review of the literature to 
identify inclusion and exclusion criteria of prospective interventional oligometastatic disease clinical trials. Next, 
we used a Delphi consensus process to select a total of 17 oligometastatic disease characterisation factors that should 
be assessed in all patients treated with radical local therapy for oligometastatic disease, both within and outside of 
clinical trials. Using a second round of the Delphi method, we established a decision tree for oligometastatic disease 
classification together with a nomenclature. We agreed oligometastatic disease as the overall umbrella term. A history 
of polymetastatic disease before diagnosis of oligometastatic disease was used as the criterion to differentiate between 
induced oligometastatic disease (previous history of polymetastatic disease) and genuine oligometastatic disease (no 
history of polymetastatic disease). We further subclassified genuine oligometastatic disease into repeat oligometastatic 
disease (previous history of oligometastatic disease) and de-novo oligometastatic disease (first time diagnosis of 
oligometastatic disease). In de-novo oligometastatic disease, we differentiated between synchronous and 
metachronous oligometastatic disease. We did a final subclassification into oligorecurrence, oligoprogression, and 
oligopersistence, considering whether oligometastatic disease is diagnosed during a treatment-free interval or during 
active systemic therapy and whether or not an oligometastatic lesion is progressing on current imaging. This 
oligometastatic disease classification and nomenclature needs to be prospectively evaluated by the OligoCare study.
Introduction
Hellman and Weichselbaum1 first proposed oligo­
metastatic disease as a distinct cancer state between 
locally confined and systemically metastasised disease in 
1995. In such patients with limited metastatic disease, 
the value of integrating local metastases­directed therapy 
into the treatment framework has been investigated in 
five randomised phase 2 studies. Three of these studies2–4 
have assessed whether or not the addition of metastases­
directed local therapy to standard­of­care systemic 
therapy improves outcome in oligometastatic disease, as 
compared with systemic treatment alone. All three 
studies reported improved progression­free survival2 or 
overall survival3,4 with the addition of metastases­directed 
local therapy. Palma and colleagues5 described an overall 
survival benefit of metastases­directed stereotactic body 
radiotherapy in addition to standard of care for patients 
with oligo metastatic disease with controlled primary 
malignancy in a tumour­agnostic trial that mostly 
involved patients with breast, lung, colorectal, and 
prostate cancer. Ost and colleagues6 did a study in 
patients with oligorecurrent prostate cancer, in which 
metastases­directed stereotactic body radiotherapy was 
compared with surveillance; systemic therapy in the 
form of androgen deprivation was not a component of 
the initial treatment strategy but was used only at disease 
progression. Androgen deprivation therapy­free survival 
was longer with metastasis­directed therapy than with 
surveillance alone. In another prostate cancer study, the 
randomised phase 3 STAMPEDE trial, the investigators 
addressed the hypothesis that local treatment of the 
primary tumour alone, without metastases­directed 
therapy, affects outcome in meta static disease. Local 
radiotherapy of the prostate was shown to improve 
overall survival in patients with a low metastatic burden, 
but not in those with a high metastatic burden, compared 
with androgen deprivation therapy only.7
Conversely, less progress has been made in under­
standing and defining oligometastatic disease based 
on tumour biology (ie, in recognising patients with 
truly limited metastatic capacity by oligometastatic 
disease­specific biomarkers).8 MicroRNA profiles, which 
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correlate with progression or differentiate oligometastatic 
and polymetastatic lung disease, have been reported9,10 as 
has an integrated molecular subtype for identifying a 
curable oligometastatic state in colorectal liver meta­
stasis.11 Dhondt and colleagues12 described a microRNA 
signature to identify oligometastatic prostate cancer. 
However, external or independent validation of these 
biomarkers has been either unsuccessful or is still 
absent.
The current scarcity of biomarkers has made imaging 
the most relevant diagnostic method for defining 
oligometastatic disease.13 Rapid advances in imaging 
that allow identification of small metastases help to 
differentiate between oligometastatic and polymetastatic 
disease, thereby excluding patients with more widespread 
disease from unnecessary local treatment. For example, 
fluorodeoxyglucose PET has been shown to improve the 
selection of patients with a low tumour burden in non­
small­cell lung cancer and colorectal cancer14,15 who might 
benefit the most from radical local metastases­directed 
treatment. The European Organisation for Research and 
Treatment of Cancer (EORTC) has identified the crucial 
role of imaging to standardise and optimise the clinical 
diagnosis of oligometastatic disease and has published 
expert recommendations.16,17 Although these recommen­
dations are intended to assist in the design of clinical 
trials, European Society for Medical Oncology (ESMO) 
clinical practice guidelines already refer to these imaging 
recommendations.18 Uncertainty remains with regards to 
the exact meaning of limited metastases; however, trial 
design and clinical practice today are rather consistent in 
limiting oligometastatic disease to a maximum of 
three to five metastases.19 Despite these improvements 
in imaging and some consensus on imaging­based 
definition of oligometastatic disease, clinical outcome 
after treatment of oligometastatic disease varies substan­
tially: a systematic literature review in oligometastatic 
non­small­cell lung cancer reported that 5­year overall 
survival ranges between 86% and 8·3%.20 This range is 
equivalent to the variation in overall survival between 
stage I and stage IV non­small­cell lung cancer.21 Several 
studies have proposed prognostic scoring systems or 
nomograms to achieve more accurate overall survival 
prediction and patient selection;22–25 however, all these 
studies are based on retrospective cohorts with potential 
bias in patient selection and none have been prospectively 
validated.
The limitations of imaging, or more precisely its 
clinical interpretation, could substantially affect clinical 
out comes. In fact, Hellman and Weichselbaum1 
described in their landmark paper two very different 
clinical scenarios, both under the umbrella of 
oligometastases: “tumors early in the chain of 
progression with metastases limited in number and 
location” and “another group of patients with 
oligometastases who had widespread metastases that 
were mostly eradicated by systemic agents, the 
chemotherapy having failed to destroy those remaining 
because of the number of tumour cells, the presence of 
drug­resistant cells, or the tumour foci being located in 
some pharmacologically privileged site”. These two 
scenarios of oligometastatic disease, which might 
present with similar features on imaging but differ 
substantially from a clinical perspective, are most likely 
associated with very different outcome and require 
different treatment strategies. Consequently, better 
characterisation and classification of the different states 
of oligometastatic disease is needed.
We have convened a group of international experts in 
diagnosis and treatment of oligometastatic disease from 
the EORTC and European Society for Radiotherapy and 
Oncology (ESTRO) OligoCare project and initiated 
this consensus process on characterisation and classifi­
cation of oligometastatic disease. We aimed to establish 
a comprehensive system of oligometastatic disease 
characterisation factors, which should be assessed in 
all patients treated with radical local treatment for 
oligometastatic disease both inside and outside of clinical 
trials. These oligometastatic disease char acterisation 
factors were the basis to develop and agree on an 
oligometastatic disease classification system and 
nomenclature that cover all possible clinical situations of 
imaging findings with few metastases. The classification 
system should be unambiguous, based on established 
prognostic patient and disease characteristics, and not 
require additional diagnostic testing. The classification 
system should also reflect fundamental biological and 
clinical processes underlying the development of 
oligometastatic disease and should be independent from 
the primary tumour type.
Methods
Data collection
This project originates from the ESTRO and EORTC 
OligoCare registry project (EORTC 1822, first cohort of 
the joint EORTC–ESTRO RADiation InfrAstrucTure for 
Europe—E2­RADIatE, EORTC 1811, NCT03818503) 
which aims to identify patient, tumour, staging, and 
treatment characteristics that affect overall survival of 
patients treated with metastases­directed radiotherapy 
for oligometastatic disease. The inclusion criteria for 
this project are broad to represent the diversity of 
daily clinical practice and to allow the identification of 
relevant prognostic and predictive factors. Patients are 
eligible irrespective of whether oligometastatic disease 
is diagnosed synchronously or metachronously and 
regardless of previous surgical, locally ablative therapy, 
and systemic treatments. Included patients can have 
been treated previously for oligometastatic or non­
oligometastatic disease.
We defined factors for oligometastatic disease 
characterisation in a two­step process, starting with a 
systematic literature review followed by a Delphi 
consensus process. All coauthors of this manuscript 
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(except DHS) are members of the OligoCare project and 
represent ESTRO or EORTC as experts in clinical trial 
design, diagnosis, and treatment of oligometastatic 
disease. All 19 members of the OligoCare project 
contributed to all parts of the Delphi consensus definition 
process.
Search strategy and selection criteria
We followed PRISMA guidelines for this systematic 
literature review.26 PubMed and Embase were searched 
for prospective clinical trials on oligometastatic disease 
published in English. Two investigators (MG and 
DHS) independently searched the databases up to 
March 24, 2019. The search terms were: ([“oligometastasis” 
OR “oligometastatic” OR “oligometastases” OR “oligo­
recurrence” OR “oligo recurrent” OR “oligoprogression” 
OR “oligoprogressive” OR “oligopersistent” OR “oligo­
persistence”] AND [“randomised” OR “randomized” OR 
“prospective”]). We also reviewed the references of 
articles included in the final selection. To be eligible, 
trials had to be prospective phase 1–3 studies (to reduce 
bias), be therapeutic interventional studies, and report 
outcome of overall survival or progression­free survival, 
or disease recurrence. Studies reporting quality of life 
only or studies limited to brain metastases were excluded. 
Two investigators (MG and DHS) independently 
reviewed the list of retrieved articles and selected 
potentially relevant articles. The same two investigators 
independently extracted study inclusion and exclusion 
criteria data from all selected studies. We did not extract 
general patient characteristics unrelated to oligo meta­
static disease (eg, age, sex, or performance status) or 
comorbidity data. We considered these study inclusion 
and exclusion criteria as factors for oligometastatic 
disease characterisation and included them into the 
Delphi process for consensus definition.
Consensus formation
We used a Delphi process to establish consensus about 
oligometastatic disease characterisation factors.27 We 
circulated surveys to all individual participants using the 
online survey tools SurveyMonkey and Google Forms. In 
round one, the participants were provided with the 
results of the systematic review. The participants were 
asked to answer one open­ended question: to describe 
potential oligometastatic disease characterisation factors 
and classification factors that had not been identified in 
the systematic review. We assumed that simultaneous or 
secondary primaries or non­malignant lesions had been 
excluded by clinical judgment, repeated or multi­method 
imaging, or biopsy confirmation. Two investigators 
(MG and DHS) consolidated all the participants’ 
responses into a list of oligometastatic disease char­
acteristics that was circulated to all participants 
in the second round of the Delphi process to assess 
whether or not consolidation did introduce misinter­
pretations of individual responses. In the third round, all 
oligometastatic disease characterisation factors, extracted 
from the systematic review and from the first two Delphi 
rounds, were provided to the participants to score each 
item on a 5­point Likert scale (1=strongly agree; 
5=strongly disagree); for each item, we asked: “should 
the oligometastatic disease characterisation factor be 
assessed in all patients treated with radical local 
treatment for oligometastatic disease inside and outside 
of clinical trials and form the basis for the case report 
forms of the prospective OligoCare registry trial, 
assessing real­world practice and outcome in this 
setting?”. A threshold of 75% or more for agreement or 
disagreement was required for each item to reach 
consensus. We analysed all responses and comments, 
recorded items reaching consensus and did not include 
these in the subsequent survey. Next, we asked the 
participants to vote again on items that had not reached 
75% or more agreement. Following this round, we 
excluded from the final recommendations any item that 
still did not have consensus. We generated a consensus 
of oligometastatic disease characterisation factors by 
combining all items that reached consensus. During this 
phase, only minor modifications to grammar and 
wording were accepted. No additions or removals of 
items were permitted.
We developed the oligometastatic disease classification 
system in a three­step process. First, descriptive tumour 
and treatment characteristics, quantitative oligometastatic 
disease characteristics, and characteristics relating to 
individual metastases were excluded as potential oligo­
metastatic disease classification factors. The remaining 
oligometastatic disease characteristics were all addressing 
the process of oligometastatic disease development and 
were formulated as binary yes or no questions. Second, a 
decision tree was established on the basis of binary 
questions. The decision tree started with imaging­based 
diagnosis of oligometastatic disease and the hierarchical 
order aimed to minimise the number of branches and 
considered the temporal course of oligometastatic 
disease development. Lastly, nomen clatures of previously 
proposed oligometastatic states1,28–33 were applied to the 
decision tree and complemented two of the oligo­
metastatic disease states, which remained unaddressed 
in the literature.
We assessed the oligometastatic disease classification 
system for consensus in a Delphi process: we provided 
the participants with the graphical overview of the 
classification system in form of a decision tree and each 
participant scored each oligometastatic disease state on 
a five­point Likert scale (1=strongly agree; 5=strongly 
disagree). We set a threshold of 75% or more for 
agreement or disagreement for each item to reach 
consensus. In a second round, we provided the 
participants with the anonymous responses from the 
previous round. Following this round, any item still 
without consensus was excluded from final recom­
mendations.
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Findings
Oligometastatic disease characterisation
The systematic review retrieved 806 publications, from 
which we selected 68 potentially relevant articles after 
abstract screening. After full­text article review, 
46 manuscripts fulfilled the inclusion criteria, and after 
exclusion of 20 duplicate records or repeated publications 
of identical clinical trials, 26 studies reporting overall 
survival or progression­free survival of prospective 
interventional trials for oligometastatic disease were 
analysed (figure 1). We identified a total of ten oligo ­
metastatic disease­related study inclusion and exclusion 
criteria in these 26 prospective trials, which were 
potential candidates for oligometastatic disease char­
acterisation factors (appendix pp 2–3).
In the first two rounds of the Delphi process (figure 2, 
appendix pp 4–5), we collected eight additional candi­
dates for oligometastatic disease characterisation and 
com bined invasive staging with imaging­based staging 
arriving at a total of 18 characteristics, which were scored 
independently in rounds 3·1 and 3·2 of the Delphi 
process (figure 2, appendix pp 6–11). After this Delphi 
consensus process, we agreed upon all ten oligometastatic 
disease characteristics identified in the systematic review 
and added seven additional characteristics to the final list 
of 17 oligometastatic disease characteristics (panel). The 
response rate of the 19 experts during the Delphi process 
was at least 89% for all rounds of the process (figure 2).
Oligometastatic disease characterisation classification
We established and agreed the oligometastatic disease 
classification system on the basis of the previously agreed 
characterisation system. After discussion, 17 (94%) of 
18 participants agreed (either strongly agreed or agreed) on 
oligo metastatic disease as the umbrella term for all states 
of limited metastatic disease, staying within the tradition 
of the original publication of Hellman and Weichselbaum.1 
Differentiation is based on five char acterisation factors 
which we identified as the basis for the oligometastatic 
disease classification system and decision tree comprising 
of a total of eight branches and a total of nine distinct states 
of oligometastatic disease (figure 3 and figure 4).
Question 1: Does the patient have a history of 
polymetastatic disease before current diagnosis of 
oligometastatic disease?
This question differentiates between genuine oligo­
metastatic disease (patients without a history of poly­
metastatic disease) and induced oligometastatic disease 
(patients with a history of polymetastatic disease). 
In genuine oligometastatic disease, the absence of 
polymetastatic disease in the patient’s history indicates a 
225 records identified through
 PubMed search
806 records screened
581 records identified through
 Embase search
738 articles excluded on the
 basis of abstract
20 duplicates excluded
68 full-text articles assessed for eligibility
46 articles included on the basis of inclusion criteria
26 articles included in qualitative synthesis
22 articles excluded on the 
 basis of inclusion criteria
 5 secondary analyses of 
 published trials
 9 registry studies
 2 retrospective studies
 5 study protocols
 1 biomarker study without 
 therapeutic intervention
Figure 1: Flowchart of article selection process
Step 1
April 1, 2019, 100% response rate
All 19 participants were asked to answer one open question: to describe 
potential oligometastasic disease characterisation factors and classification 
factors in addition to the ones identified in the systematic review
Step 2
April–May, 2019, 100% response rate
The consolidated list of nine additional oligometastasis disease characteristics 
was circulated to all participants who could then agree or disagree on 
consolidation; consolidation was approved for all items
Step 3·1
May–June, 2019, 89% response rate
All ten oligometastasis disease characterisation factors from the systematic 
review and eight from the first two Delphi rounds were provided to the 
participants to score each item on a 5-point Likert scale; 17 items were
approved
Step 3·2
June, 2019, 100% response rate
Participants were asked to vote again on one single item (“Is the
oligometastasic lesion pathologically proven?”) that had not reached 
>75% agreement; this item was not approved
Step 4
June–July, 2019, 95% response rate
Participants were provided with the graphical overview of the oligometastasis
disease classification system in the form of a decision tree and each 
oligometastasis disease state was scored by each participant on a 5-point 
Likert scale; all items were approved
Figure 2: Schematic overview of the Delphi process
See Online for appendix
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low metastatic capacity of cancer. Induced oligo metastatic 
disease has already been described by Hellman and 
Weichselbaum:1 “the chemotherapy (or more in general 
systemic therapy) having failed to destroy (or control) 
those remaining (metastases) because of the number of 
tumour cells, the presence of drug­resistant cells, or the 
tumour foci being located in some pharmacologically 
privileged site”. Induced oligometastatic disease does 
therefore not indicate a possible low metastatic capacity, 
as is the case in genuine oligometastatic disease, but 
rather a state of disease, which is the result of 
polymetastatic disease treated with systemic therapy with 
or without local therapy.
Question 2: Does the patient have a history of 
oligometastatic disease before the current diagnosis of 
oligometastatic disease?
For patients with genuine oligometastatic disease, this 
question differentiates between de­novo oligometastatic 
disease (patients without a previous diagnosis of oligo­
metastatic disease) and repeat oligometastatic disease 
(patients with a previous diagnosis of oligo metastatic 
disease). De­novo oligometastatic disease is the classic 
state of the disease as initially described by Hellman and 
Weichselbaum.1 For patients with a previous diagnosis of 
oligometastatic disease, who have not progressed to 
polymetastatic disease after failure to local and systemic 
treatment, repeat oligometastatic disease might represent 
a cancer with favourable biology of low metastatic capacity 
over a long period of time. Polymetastatic disease is the 
most frequent failure pattern after treatment of oligo­
metastatic disease, but some studies report that repeat 
oligometastatic disease is observed in 27–75%.34–36
Question 3: Has oligometastatic disease been first 
diagnosed more than 6 months after the primary cancer 
diagnosis?
For patients with de­novo oligometastatic disease, this 
question differentiates between synchronous oligo­
metastatic disease (maximum 6 months interval between 
diagnosis of oligometastatic disease and primary cancer 
diagnosis) and metachronous oligo metastatic disease 
(more than 6 months interval between diagnosis of 
oligometastatic disease and primary cancer diagnosis). 
No consensus exists in the literature about the interval 
between primary cancer diagnosis and the develop­
ment of oligometastatic disease to differentiate between 
synchronous and metachronous disease;29 however, 
diagnosis of oligo metastatic disease more than 6 months 
after diagnosis of the primary tumour has been a 
frequently used definition for metachronous instead of 
syn chron ous oligometastatic diease.37,38 Although most 
studies report that synchronous oligometastatic disease is 
associated with a more aggressive disease phenotype 
and a worse prognosis than metachronous oligometa­
static disease,22,39,40 these predictions were not confirmed 
by all studies.41,42
Question 4: Is the patient under active systemic therapy 
at the time of oligometastatic disease diagnosis?
For patients with metachronous oligometastatic disease, 
repeat oligometastatic disease, and induced oligometa­
static disease, development of oligometastatic disease in a 
treatment­free interval or during active systemic therapy is 
differentiated. Diagnosis of metachronous oligometastatic 
disease with the patient under active systemic therapy 
indicates metachronous oligo progression. This state of 
oligometastatic disease is more frequently expected in 
those cancers that are treated with long­term systemic 
therapy at primary diagnosis (eg, androgen deprivation 
therapy for high­risk prostate cancer, endocrine therapy for 
breast cancer, or targeted therapy for driver­mutated 
non­small­cell lung cancer). The finding of repeat 
Panel: Characteristics of oligometastatic disease
Descriptive tumour characteristics
• Primary tumour characteristics: primary tumour site, 
histology, stage according to TNM Classification of 
Malignant Tumours, mutational status, tumour marker
• History of cancer progression: time interval since first 
diagnosis, disease-free interval, treatment-free interval
• History of treatment of primary tumour: method of 
local treatment, radical or palliative intent, controlled 
primary tumour
• History of systemic therapy before diagnosis of 
oligometastatic disease: types of systemic therapy, 
number of lines of systemic therapy
• Oligometastatic disease staging: imaging method, 
anatomical areas covered, invasive staging
• Involved organs of oligometastatic disease
Quantitative characteristics
• Number of metastatic lesions
• Number of involved organs
• Number of lesions per organ
• Maximum size or volume of individual metastasis
Developmental characteristics
• Does the patient have a history of polymetastatic disease 
before oligometastatic disease diagnosis?
• Does the patient have a history of oligometastatic disease 
before current diagnosis?
• Is oligometastatic disease diagnosed within 6 months 
after diagnosis of the primary tumour?
• Is the patient under active systemic therapy at the time of 
oligometastatic disease diagnosis?
• Are any oligometastatic lesions progressive on current 
imaging?
Metastases-specific characteristics
• Is the oligometastatic lesion a newly developed 
metastatic lesion?
• Is treatment of the oligometastatic lesion possible with 
radical intent?
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oligometastatic disease and induced oligometastatic 
disease with the patient under active systemic therapy 
requires further sub­classification by question five and is 
explained below. Metachronous, repeat, and induced 
oligometastatic disease in patients not under active 
systemic therapy indicates oligorecurrence: the cancer 
responded well to local treatment, systemic treatment, or 
both, which allowed a treatment­free interval, and disease 
recurred later presenting as only a small number. The 
term oligo refers to the small number of growing or newly 
developed metastases; patients with induced oligorecur­
rence might have additional stable metastases, and the 
value of treating these stable metastases is currently 
unclear.
Question 5: Are any oligometastatic lesions progressive 
on current imaging?
For patients with repeat oligometastatic disease and 
induced oligometastatic disease under active systemic 
treatment, this question differentiates between 
oligoprogression (progressive disease on current 
imaging) and oligopersistence (stable disease or partial 
response on current imaging). The term oligo refers 
to a few growing or newly developed metastases 
(oligopro gression) or a few persistent metastases (oligo­
persistence). Patients with induced oligoprogression 
or induced oligopersistence might have additional 
metastases, which are controlled by or respond to 
systemic therapy; the value of treating these 
nonprogressive and non persistent metastases locally is 
currently unclear.
To the best of our knowledge, no data about the 
incidence and prognosis of repeat oligoprogression and 
repeat oligopersistence are available. Induced oligo­
progression is a well­recognised state of oligometastatic 
disease: several studies have been done in patients with 
oligoprogressive non­small­cell lung cancer, in whom 
systemic therapy achieved good responses of poly­
metastatic disease but only a few metastases developed 
resistance and progressed later on; local ablative 
Imaging-based diagnosis
of oligometastatic 
disease
Genuine
oligometastatic
disease
Induced 
oligometastatic
disease
Induced 
oligorecurrence
Repeat
oligometastatic
disease
De-novo 
oligometastatic
disease
Induced 
oligometastatic
disease
Induced 
oligopersistence
Repeat
oligoprogression
Metachronous
oligorecurrence
Metachronous
oligoprogression
Repeat
oligopersistence
Induced 
oligoprogression
Synchronous
oligometastatic
disease
Metachronous
oligometastatic
disease
Repeat
oligorecurrence
Repeat
oligometastatic
disease
Q1
No
Yes
Q5
No
Yes
Q4
No
Yes
Q2
No
Yes
Q4
No
Yes
Q3
No
Yes
Q5
No
Yes
Q4
No
Yes
Figure 3: Decision tree for classification of oligometastatic disease
The decision tree starts with oligometastatic disease as umbrella term. Questions 1 and 2 differentiate between the upper-level oligometastatic states of de-novo (red), repeat (blue) and induced 
oligometastatic disease (green). Question 3 differentiates de-novo oligometastatic disease into synchronous and metachronous oligometastatic disease. Questions 4 and 5 subclassify into 
oligorecurrence, oligoprogression, and oligopersistence. Q1: Does the patient have a history of polymetastatic disease before current diagnosis of oligometastatic disease? Q2: Does the patient have a 
history of oligometastatic disease before current diagnosis of oligometastatic disease? Q3: Has oligometastatic disease been first diagnosed more than 6 months after the primary cancer diagnosis? 
Q4: Is the patient under active systemic therapy at the time of oligometastatic disease diagnosis? Q5: Are any oligometastatic lesions progressive on current imaging?
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treatment was combined with either continuation of 
systemic therapy43–47 or switch to the next treatment 
line.48 In patients with induced oligopersistence, only 
stable disease or partial response is achieved in a few 
metastases, whereas a prolonged partial response or 
complete response is observed in the remaining poly­
metastatic disease. Both randomised trials in oligo­
metastatic non­small­cell lung cancer enrolled patients 
with stage IV non­small­cell lung cancer after 
completing systemic therapy, irrespective of their 
tumour burden at their primary cancer diagnosis; the 
oligometastatic state was defined at the time of restaging 
after first­line therapy.2,4 Consequently, heterogeneous 
patients could have been recruited into these trials: 
ie, a mixture of patients with chemotherapy­resistant 
or targeted therapy­resistant genuine oligo metastatic 
disease and patients with induced oligopersistence, in 
whom systemic treatment of poly metastatic disease 
achieved a complete response except for a few resistant 
metastases.
Treatment strategies and goals
Traditionally, local treatment for metastatic disease, 
irrespective of oligometastatic or polymetastatic state, 
was exclusively done with palliative intent. The systemic 
treatment strategy was dependent on several factors, 
including patient characteristics such as age and 
comorbidities; primary cancer type and molecular 
disease features; pattern, volume, and kinetics of disease 
progression; presence of symptoms; previous history of 
cancer treatment such as response to systemic treatment 
or disease­free interval; availability of current and future 
systemic therapy options, and their efficacy and toxicity 
profile; and patient’s preference.
Both treatment goals and treatment strategies have 
changed with the introduction of the concept of 
oligometastatic disease. In clinical trials, overall survival, 
progression­free survival, avoidance of systemic therapy 
(eg, androgen­deprivation therapy in oligometastatic 
prostate cancer), and quality of life are the most 
frequently defined endpoints.31,49 Whereas local treatment 
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   oligometastases (red) within 6 months
• T-X: diagnosis and treatment of primary cancer (green) in a 
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• Systemic therapy-free interval
• T0: First time diagnosis of new oligometastases (red) >6 months 
 after diagnosis of cancer
• T-X: diagnosis and treatment of primary cancer (green) in a 
 non-metastatic state
• Under treatment with active systemic therapy
• T0: first time diagnosis of new oligometastases (red) >6 months
 after diagnosis of cancer
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• T-X: diagnosis of oligometastases followed by local treatment or
 systemic treatment or both
• Under treatment with active systemic therapy
• T0: diagnosis of new (blue) and growing or regrowing (red) 
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 by systemic treatment with or without local treatment
• Systemic therapy-free interval
• T0: diagnosis of new (blue) and growing or regrowing (red) 
 oligometastases, possible residual non-progressive metastases
 (black)
• T-X: diagnosis of polymetastatic metastatic disease followed 
 by systemic treatment with or without local treatment
• Under treatment with active systemic therapy
• T0: diagnosis of new (blue) and growing or regrowing (red) 
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Figure 4: Illustration of the oligometastatic disease classification system
(A) De-novo oligometastatic disease. (B) Induced oligometastatic disease. (C) Repeat oligometastatic disease. In repeat and induced oligometastatic disease the primary tumour is assumed to be 
controlled by ongoing or previous treatment. Oligometastases are confirmed by imaging or biopsy to exclude simultaneous or secondary primary tumours. T0=at this current point of time. T-x=any 
previous point in time.
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aims to eradicate all oligometastases and the potentially 
uncontrolled primary tumour, the choice of the optimal 
combination strategy with systemic treatment depends 
on the oligometastatic disease state, the specific treat­
ment goal, and the factors mentioned.
For all states of de­novo oligometastatic disease and 
repeat oligometastatic disease, radical treatment aims to 
achieve a status of freedom from disease. Translation of 
such status into prolonged overall survival or cure will 
depend on the efficacy of local treatment and on the 
absence or effective control of occult metastatic disease 
by the addition of systemic therapy. Consequently, all 
but one6 randomised trials in oligometastatic disease 
published so far used standard systemic therapy as a 
backbone of the oligometastatic disease treatment 
strategy.2–5 The choice of the optimal systemic therapy is 
especially unclear in metachronous oligoprogression, in 
which oligometastatic disease develops during active 
systemic therapy in the context of primary treatment, 
and continuation of systemic therapy or switching to 
another drug are sensible options. Synchronous 
oligometastatic disease adds another level of complexity 
because local treatment to the locoregional primary 
tumour, local treatment of all oligometastases, and 
systemic treatment all need to be combined into 
one treatment strategy. However, another goal of the 
local intervention in de­novo oligometastatic disease and 
repeat oligometastatic disease could be to prolong the 
time until systemic therapy is needed for polymetastatic 
disease and thereby maintain the patient’s quality of life. 
This strategy has been tested for oligorecurrent prostate 
cancer, for which local metastases­directed therapy 
considerably prolonged the time until initiation of 
androgen deprivation therapy.6
Treatment goals and strategies are different in induced 
oligometastatic disease. These patients have poly­
metastatic disease, which is converted into a state of 
induced oligometastatic disease by partially effective 
systemic treatment. Local treatment for induced oligo­
metastatic disease therefore complements the systemic 
treatment and not vice versa as is the case in genuine 
oligometastatic disease. Consequently, based on currently 
available evidence, cure is not achieved in most patients.
For patients with induced oligorecurrence, radical 
local treatment aims to restore a status of stable disease 
(in case of stable residual polymetastatic disease) or a 
status of complete response (in case of complete response 
of previous polymetastatic disease). The addition of 
systemic therapy could potentially enhance the effect of 
the local intervention. Whether systemic therapy is best 
performed as re­challenge with the previous line of 
treatment—which achieved stable disease or complete 
response and a systemic therapy­free interval thereafter—
or switch to the next line of treatment is unknown. 
Another goal of the local intervention could be to prolong 
the systemic therapy­free interval.
For patients with induced oligoprogression, radical 
local treatment aims to restore a status of overall 
sensitivity to systemic therapy through eradication of 
oligometastases with resistance to the current line of 
systemic therapy. For patients with induced oligo­
persistence, the goal of radical local treatment is to 
achieve an overall deeper response to systemic therapy by 
eradication of oligometastases with reduced sensitivity to 
the current line of systemic therapy. In both induced 
oligoprogression and induced oligopersistence, contin­
uation of the current systemic therapy or switching to the 
next line of systemic therapy are possible options. The 
decision depends on the previous depth and duration of 
response, the volume and kinetics of progressive disease, 
associated symptoms, tolerability of the current and next 
Cancer history without previous diagnosis
of oligometastatic disease
De-novo oligometastatic disease
Polym
etastatic disease
Synchronous oligometastatic disease
Repeat oligometastatic disease
Metachronous 
oligorecurrence
Metachronous 
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Repeat oligorecurrence 
Repeat 
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Induced oligorecurrence
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Figure 5: Dynamic oligometastatic state model
The model illustrates pathways for developing multiple and different states of 
oligometastatic disease throughout a patient’s disease history. Patients might 
have de-novo oligometastatic disease or develop induced oligometastatic disease 
via polymetastatic disease as first-time diagnosis of oligometastatic disease. 
Repeat oligometastatic disease might develop as a degree of failure after 
treatment of de-novo oligometastatic disease; induced oligometastatic disease 
might develop after systemic failure following treatment of de-novo and repeat 
oligometastatic disease. Patients with repeat oligometastatic disease and 
induced oligometastatic disease might have dynamic transitions between 
oligorecurrent, oligoprogressive, and oligopersistent disease, depending on the 
response to local and systemic therapy.
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line of systemic treatments, and likely efficacy of the next 
line of systemic treatment.
Dynamic oligometastatic state model
The proposed oligometastatic disease classification 
system defines the oligometastatic state at one timepoint 
in the patient’s history. However, one patient might 
develop several and different states of oligometastatic 
disease throughout the course of disease, resulting in 
multiple courses of radical local and systemic treatment. 
Similar to the clinical states model proposed for prostate 
cancer,50 we therefore propose a dynamic oligometastatic 
state model (figure 5). First­time diagnosis of oligo­
metastatic disease might occur as de­novo oligometastatic 
disease or as induced oligometastatic disease after 
systemic therapy of polymetastatic disease. Repeat oligo­
metastatic disease might be the consequence of failure 
after treatment of de­novo oligometastatic disease, with 
failure being again limited to a few metastases. Following 
local ablative therapy with or without systemic therapy of 
de­novo or repeat oligometastatic disease, cancer might 
progress into polymetastatic disease. This situation will 
trigger initiation of systemic therapy, which might result 
in induced oligometastatic disease. Within repeat 
oligometastatic disease and within induced oligo meta­
static disease, patients can have dynamic trans itions 
between oligo recurrent, oligoprogressive, and oligo per­
sistent disease, depending on the response to local and 
systemic therapy.
For the three upper­level states of de­novo oligo metastatic 
disease, repeat oligometastatic disease and induced 
oligometastatic disease, transition to any downstream state 
is possible, which is then unidirectional in the patient’s 
history. Notwithstanding, transition from one oligo­
metastatic state to another is not necessarily associated 
with a worsening of the prognosis. A patient with several 
courses of treatment for repeat oligo metastatic disease 
most likely has a disease pheno type with truly limited 
metastatic capacity because no progression to poly­
metastases has developed.51 Additionally, patients with 
induced oligometastatic disease might have long­term 
survival when radical local treatment is combined with 
effective systemic treatment, such as targeting drugs for 
non­small­cell lung cancer with driver mutations or 
immunotherapy for malignant melanoma.
Clinical data support this dynamic oligometastatic state 
model with several sequential courses of radical local 
therapy for oligometastatic disease. A registry study on 
oligometastatic non­small­cell lung cancer reported that 
6·6% of all patients treated for oligo metastatic non­
small­cell lung cancer received more than one course of 
treatment and a maximum of four courses of metastases­
directed stereotactic body radiotherapy.51 Similarly, 
complex and long histories of oligometastatic disease, 
with up to maximum of four courses of radical local 
treatment, have been reported for prostate cancer.35 
A patient case example with multiple course of 
metastases­directed therapy for different states of oligo­
metastatic disease is given in the appendix p15.
Implementation
The proposed oligometastatic disease characteristics 
should be assessed in all patients with cancer treated 
with radical local treatment for oligometastatic disease, 
although use of the classification as a definitive decision­
making tool remains to be established. These char­
acteristics should enable harmonisation of reporting of 
patients treated for oligometastatic disease and therefore 
allow outcome analyses of improved quality. In the 
context of clinical trials, the harmonised oligometastatic 
disease characterisation system will contribute to a better 
understanding and interpretation of study results and 
facilitate cross­study comparisons, as well as meta­
analyses and systematic reviews. Acceptance and imple­
mentation of oligometastatic disease­related clinical 
trials into clinical practice will be facilitated by a clear and 
unambiguous classification system and nomenclature.
Conclusions
In summary, we have established a system for com­
prehensive characterisation of oligometastatic disease, 
which should be assessed in all patients with oligo­
metastatic disease treated with radical local therapy 
within and outside of clinical trials. We have developed 
an oligometastatic disease classification system on 
the basis of a decision tree of five binary disease 
characterisation factors and we have proposed a dynamic 
oligometastatic state model. We envisage to teste these 
states of oligo metastatic disease in the OligoCare 
prospective cohort trial (NCT03818503) to assess their 
prognostic value and their acceptance and compliance in 
routine practice.
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